Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Parathyroid Neoplasms 1Parathyroid Diseases 1Opioid-Related Disorders 1Non-Muscle Invasive Bladder Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Goiter 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cancer Cachexia 1Brain Neoplasms 1Agnosia 1Adenocarcinoma of Lung 1

Interventions

Aprepitant 3desloratadine 1Lidocaine 1Capsules 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pruritus × Capsules × Clear all
NCT06931119 2025-04-17

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

Rabin Medical Center

Phase 1 Not yet recruiting
30 enrolled

Pruritus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡